RVO biomarkers can be established using an AI that draws out from intravenous fluorescein angiography and baseline characteristics.

KOCHI: 68-year-old Thankamma (name changed) from Ernakulam has been a diabetic patient for 15 years. As she did not manage ...

Canaccord Genuity analyst John Newman has maintained their bullish stance on REGN stock, giving a Buy rating today. John Newman has given his ...

Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...

With U.S. sales of $392 million in the third quarter, Regeneron’s high-dose version of Eylea is closing in on blockbuster sales in its first full year on the market. The bad news for the company, ...

Reports Q3 revenue $3.72B, consensus $3.67B. “Regeneron (REGN) had a strong third quarter marked by 11% revenue growth. We continued to ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2024 and provided a business update. "Regeneron had a strong third quarter marked by 11% ...